Výsledky vyhledávání - "Eliza Germano"

Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial

Autor: Kevin Barton, Sucha Nand, John E. Godwin, Scott E. Smith, Karen Rychlik, Eliza Germano, Patrick J. Stiff, Ranjitha Veerappan, Laura C. Michaelis, Serhan Alkan

Publikováno v: Leukemialymphoma. 49(11)

Elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) have a poor prognosis due to low response rates (26-46%) to standard chemotherapy and high treatment-related mortality (11-31%). In this Phase II study,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6f9cdb9a3f901741f091f7cce66e252
https://pubmed.ncbi.nlm.nih.gov/19021057

Zobrazit plný text záznamu

Plný text ve formátu HTML

Title: Promoter Methylation of Selected Genes and Response to Azacitidine (AZ) Therapy in Patients with Non-BCR-ABL Myeloproliferative Disorders (MPDs)

Autor: Laura C. Michaelis, Nancy J. Zeleznik-Le, Scott E. Smith, Sucha Nand, Eliza Germano, Nicholas J. Achille

Publikováno v: Blood. 118:4625-4625

Abstract 4625 Background: Gene silencing via methylation of CpG islands in the promoter regions of many genes but specifically of APAF1, p15INK4B, p16INK4A, RARB, and CDH1 appears to play a role in pathogenesis of myeloid malignancies. Azacitidine (A

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::24c1016056387c00cbff5444085e6093
https://doi.org/10.1182/blood.v118.21.4625.4625

Zobrazit plný text záznamu

13 Treatment of acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) in the elderly with azacitidine and gemtuzumab ozogamicin (GO)

Autor: Sucha Nand, Eliza Germano, Sonali M. Smith, Kevin Barton, John E. Godwin, Patrick J. Stiff

Publikováno v: Leukemia Research. 31:S8

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e080ae5ef7351d59ec80b3fe42c819ed
https://doi.org/10.1016/s0145-2126(07)70014-0

Zobrazit plný text záznamu

Azacitidine Plus Gemtuzumab Ozogamicin (GO): A Novel Combination in the Treatment of Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS) in the Elderly

Autor: Patrick J. Stiff, Sucha Nand, John E. Godwin, Eliza Germano, Kevin Barton, Scott E. Smith

Publikováno v: Blood. 108:1981-1981

AML and high-risk MDS in the elderly carry a poor prognosis. Only 46% of AML patients receiving standard chemotherapy achieve complete remission (CR) and treatment-related mortality approaches 30% above age 60. In 2005, we initiated a Phase II trial

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a4f19c63b0762428e924f08356e31649
https://doi.org/10.1182/blood.v108.11.1981.1981

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání